In April 2007, Genzyme implemented measures to manage the limited supply of Myozyme® (alglucosidase alfa) in the United States in order to ensure uninterrupted treatment for as many patients as possible.  Since April, both the patient and physician communities have worked diligently to enroll the majority of adults into the Myozyme Temporary Access Program (MTAP) and have greatly reduced the number of individuals at risk of an interruption in treatment.  In spite of this achievement, not enough adults were transitioned into MTAP to ensure that the remaining infants, children and adults would have a steady supply of commercial Myozyme until the larger scale manufacturing process is approved by the FDA. Unfortunately, it is necessary to take immediate additional measures to manage the current limited commercial supply of Myozyme.

Download complete article